At a glance
- Originator Boehringer Ingelheim Pharma KG
- Class Antiplatelets; Small molecules; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 13 Jun 2001 Discontinued-Preclinical for Thrombosis in Germany (Unknown route)
- 12 Feb 2001 Profile reviewed but no significant changes made
- 03 Jun 1997 No-Development-Reported for Thrombosis in Germany (Unknown route)